Found 30 clinical trials
Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides
in patients with SOR to second-line antivirals Lamivudine (LAM)/ Telbivudine (LdT)/ Adefovir Dipivoxil (ADV) and its combinations with other second-line antivirals for 24 weeks, or SOR to the first
- 0 views
- 21 Feb, 2022
- 10 locations
Tenofovir Alafenamide(TAF) Reduces the Risk of Hepatocellular Carcinoma(HCC) Recurrence
, high HBV viral load is associated with the risk of HCC recurrence after surgical resection, especially on late recurrence. In one previous randomized controlled trial, patients who received lamivudine
- 0 views
- 19 Jul, 2021
- 4 locations
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg
part of the fixed dose combination (FDC) of DOR/lamivudine (3TC)/tenofovir disproxil fumarate (TDF) in participants ≥6 to <12 years and weighing ≥14 to <45 kg. The second primary objective is to
- 0 views
- 22 Sep, 2022
- 13 locations
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase
- 188 views
- 11 Aug, 2022
- 16 locations
Body Composition Sub-study of the D2EFT Trial
This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will offer …
- 9 views
- 21 Feb, 2022
- 7 locations
Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)
Phase III, randomized, open-label, multicentre, active-controlled, non-inferiority study evaluating the efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill
- 0 views
- 05 Aug, 2021
- 23 locations
Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)
Protocol Title: DOLCE: Dolutegravir-Lamivudine for naïve HIV-Infected Patients with ≤200 CD4/mm3 Protocol Number: FH-57 Study Objectives: To assess the antiviral activity at week
- 0 views
- 27 Jul, 2022
- 8 locations
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial (MILED)
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
- 76 views
- 22 Mar, 2022
- 4 locations
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
This phase II trial studies the effect of lamivudine in combination with standard of care chemoimmunotherapy in treating patients with extensive stage small cell lung cancer. Even though small
- 0 views
- 26 Mar, 2022
- 1 location
Changes in Weight Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals
Randomized controlled parallel open-label study in people living with HIV and at least 6 month of treatment with dolutegravir/abacavir/lamivudine prior to inclusion. Participants (n=95
- 0 views
- 02 Jun, 2021
- 5 locations